Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Lower Urinary Tract Symptoms

ConditionBenign Prostate Hypertrophy(BPH)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

Age40-80

SponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

About this trial

The study aims to investigate, through the International Prostatic Symptoms Score (IPSS) questionnaire, the non-inferiority of the therapy with the alpha-blockers+Serenoa repens combination compared to the alpha-blockers+antimuscarinic combination on storage lower urinary tract syndrome (LUTS) in patients with moderate-severe symptomatic benign prostatic hyperplasia (BPH).

Eligibility criteria

Qualifiers

Age 40-80 inclusive

Male

With moderate-to-severe LUTS from BPH according to IPSS score

Placed on AB+Serenoa repens or AB+antimuscarinics for 6 months

Disqualifiers

Prostate or bladder cancer

History of neurogenic bladder

Urinary tract abnormalities (including urethral strictures)

Trial design

Treatments tested in this trial

Not listed

Trial groups

50 Participants

are grouped into 2 trial groups

Locations

This trial has no locations

Sponsors and collaborators

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Lead sponsor

Source ClinicalTrials.gov